46 results about "Bilirubin" patented technology

The invention provides an adsorbent capable of simultaneously adsorbing bilirubin and cytokines and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out suspension polymerization reaction on a styrene monomer and a polyvinyl cross-linking agent in a dispersion medium under the action of a continuous multi-component pore-foaming agent and an initiator to prepare polystyrene-based macroporous resin; carrying out chloromethylation reaction on the polystyrene-based macroporous resin to prepare chlorine balls; carrying out post-crosslinking reaction on the chloromethylated beads to prepare the adsorbent capable of adsorbing bilirubin and cytokines at the same time; the continuous multi-component pore-foaming agent comprises a first pore-foaming agent, a second pore-foaming agent and a third pore-foaming agent of which the solubility parameters are gradually increased in sequence; the temperature of the suspension polymerization reaction is adjusted according to the mass fraction of the polyvinyl cross-linking agent in the monomer mixture and the solubility parameter of the continuous multi-component pore-foaming agent, and the monomer mixture is composed of styrene monomers and the polyvinyl cross-linking agent. The bilirubin and cell factors can be adsorbed at the same time, and the safety of blood purification is improved.

The invention relates to the technical field of blood purification materials, in particular to a zirconium-titanium bimetal MOF hollow microsphere adsorbent and a preparation method and application thereof. The adsorbent is based on a Zr / Ti bimetallic node and a phosphonic acid-carboxylic acid mixed ligand, a composite MOF hollow microsphere structure with high stability and high specific surface area is constructed through a solvothermal and polymerization synergistic reaction in a water-in-oil suspension system, a phosphonic acid group and Zr are strongly coordinated to improve the stability of a framework, and the composite MOF hollow microsphere structure has a high specific surface area. The carboxylic acid group keeps the hydrophilicity of the pore channel; meanwhile, a cross-linked network of acrylamide and N, N '-methylene bisacrylamide penetrates through crystal gaps in the balling process, so that the material has excellent mechanical strength and fluid stability; and a sulphobetaine amphoteric polymer brush layer is constructed on the surface of the MOF through endogenous initiation point modification and surface in-situ controllable free radical polymerization technologies, so that protein adsorption and platelet adhesion are effectively inhibited, the blood compatibility is remarkably improved, and meanwhile, the channel accessibility is maintained to promote rapid diffusion and adsorption of bilirubin.

An eyeshade structure for bilirubin detection includes a body, a first detection module, and a second detection module. The body includes a bottom plate and a side wall. The side wall is connected to the bottom plate and forms an accommodating space with the bottom plate. The first detection module is arranged on the bottom plate. The second detection module is arranged on the bottom plate and is adjacent to the first detection module. The first detection module and the second detection module each include a circuit board, a light-emitting element, an inner photographing element, and an outer photographing element. The circuit board is connected to the bottom plate. The light-emitting element is electrically connected to the circuit board. The inner photographing element is electrically connected to the circuit board. The outer photographing element is electrically connected to the circuit board.

This invention provides a process for extracting biliverdin hydrochloride through bio-fermentation and a method for synthesizing bilirubin. By studying the complex system of biliverdin obtained through microbial bacterial fermentation, a process for separating and purifying biliverdin was established, and the obtained biliverdin was further used to synthesize bilirubin. This process is simple to operate, uses common resins, employs solvents with low toxicity that are easily recovered and reused, utilizes low-energy membrane separation equipment for concentration, and uses conventional reaction reagents as reducing agents. The process has low operating costs, is environmentally friendly, and yields high-purity and stable-yield biliverdin and bilirubin products, demonstrating excellent prospects for industrial application.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a compound bezoar composition, decoction piece type compound bezoar and a preparation method of the decoction piece type compound bezoar. The compound calculus bovis composition provided by the invention comprises 94-96% by mass of main agents and 8 kinds of calculus bovis intermediates, the mass content of the auxiliary agent is 4-6%, and the auxiliary agent is six commercially available finished product combined cholic acid. The bilirubin content of the bezoar intermediate used in the invention is increased by more than 30% and the yield is increased by more than 25% compared with the existing biochemical reaction process of oxgall. The DPPH free radical scavenging rate of the compound bezoar composition reaches 89.6% + / -2.1% and is increased by 25.7-36.9% compared with 58.3% + / -3.5% of a product prepared from ox bile, and through t inspection, p is smaller than 0.01 (n is equal to 5). Free cholic acid intervention is strictly prohibited, lithocholic acid addition is completely eradicated, and the composition has the advantages of being high in bilirubin content, high in oxidation resistance and high in biological activity and adapts to the physiological characteristics of the human body.

This invention discloses a single-herb bezoar preparation based on an ancient prescription; an enteric-coated bezoar soft capsule and its preparation method. The enteric-coated bezoar soft capsule consists of a bezoar dispersion and an enteric-coated soft capsule shell. A sand mill is used to prepare bezoar powder into micron-sized particles with a particle size ≤100μm. The micron-sized bezoar powder is fully dispersed in a dispersion medium, thereby improving the solubility of bezoar. The single-herb bezoar preparation can improve the problem of inconsistent bezoar content in compound bezoar preparations. The process of preparing the ≤100μm micron-sized bezoar dispersion uses non-metallic grinding equipment, avoiding the catalytic reaction of metal ions during the preparation of micron-sized powder. Low-temperature grinding is also used to avoid denaturation of the heat-sensitive active substances in bezoar, better preserving its biological activity. The enteric-coated formulation prevents the drug from being released in the stomach until it reaches the small intestine, avoiding the precipitation of bilirubin and other bile acids in the acidic environment of the stomach, which would otherwise lead to insoluble solids and poor solubility.

The application belongs to the field of biological detection, and particularly relates to a technology and a reagent for detecting NAG by a VRA-NAG substrate method. The linear range of the NAG detection reagent provided by the application can reach (0, 500] U / L; within the range, when the anti-acid is less than or equal to 340 micromoles / L, urea is less than or equal to 42.9 millimoles / L, uric acid is less than or equal to 1.4 millimoles / L, albumin is less than or equal to 100 milligrams / dL, bilirubin is less than or equal to 342 micromoles / L, lactic acid is less than or equal to 6.6 millimoles / L, glucose is less than or equal to 55 millimoles / L, triglyceride is less than or equal to 37 millimoles / L, and oxalic acid is less than or equal to 81 micromoles / L, these components have no obvious interference on the test. Moreover, the relative standard deviation caused by the accelerated aging of the detection reagent for 10 days is not more than ±10%. Compared with the prior art, the kit provided by the application has high sensitivity, wide linear range, strong specificity and good stability, and is conducive to early detection and early treatment of kidney diseases in clinical practice.

The invention discloses a method for culturing calculus bovis by utilizing flora, which is characterized in that cattle gall bladders obtained by slaughtering are used as reaction containers, so that the animal welfare problem caused by living body surgery is completely avoided. A plurality of key steps of bilirubin generation, cholesterol conversion, matrix formation and the like are synergistically completed by adopting functional complementary synthetic flora, and the components of the generated product are closer to a complex system of natural calculus bovis. The breeding is carried out in a closed bioreactor with controllable parameters, uncontrollable factors such as individual cattle difference and feeding environment are eliminated, and the product quality is highly stable and uniform. Automatic monitoring and feedback control are achieved in the whole cultivation process, and technological parameters are accurate and adjustable. The used strains are all non-pathogenic or food-grade safe strains, and the whole process is sterile, free of exogenous pathogen pollution and antibiotic residue risks, and high in biological safety.

The application belongs to the technical field of medical equipment, and provides a blood treatment system including a blood treatment assembly, an optical detection assembly and a control module. The blood treatment assembly uses a treatment liquid to treat blood of a target object to obtain waste liquid and treated blood, and the treated blood is transfused back to the target object. The optical detection assembly generates irradiation light of at least three wavelengths, wherein the irradiation light of the first wavelength is used for detecting bilirubin or free hemoglobin, the irradiation light of the second wavelength is used for detecting intracellular hemoglobin, and the irradiation light of the third wavelength is used for detecting the waste liquid. The optical detection assembly collects light information of emergent light of the at least three wavelengths. The control module obtains light change information corresponding to the at least three wavelengths according to the light information of the emergent light of the at least three wavelengths and the light information of the irradiation light of the at least three wavelengths. Whether the light change information corresponding to the at least three wavelengths satisfies a preset alarm condition is judged to determine whether to perform a hemolysis alarm or a blood leakage alarm, so that detection is distinguished.

The present application belongs to the technical field of medical apparatus and instruments, and discloses a warm box closed blue light irradiation data management system based on mechanical intelligence, which comprises: a state cluster data module, which collects multi-source heterogeneous data, corrects the clock deviation between the warm box and the preset biological sensor through a space-time alignment protocol, dynamically adjusts the multi-source heterogeneous data sampling rate based on the infant physiological data in the multi-source heterogeneous data after time alignment, and outputs a state cluster data packet with a time stamp; a hierarchical extraction module, which constructs a three-level feature processing pipeline based on the state cluster data packet, including a basic layer that calculates basic statistics through a sliding window; a logic layer that generates a temperature-light effect index and a sealing safety coefficient according to the basic statistics and in combination with the multi-source heterogeneous data; and a decision layer that establishes a treatment efficiency prediction matrix based on the temperature-light effect index and the sealing safety coefficient, and predicts the associated trend of blue light irradiation and bilirubin metabolism; the safety and curative effect stability of infant treatment are improved.

The invention discloses an image processing method and device for judging suspension red blood cell hemolysis. The method comprises the following steps: acquiring a blood image set; the blood image set comprises a plurality of blood images and corresponding label information; acquiring a blood parameter information set; the blood parameter information set comprises a plurality of blood parameters and corresponding label information; the blood parameters comprise hemoglobin concentration, reticulocyte concentration, indirect bilirubin concentration, lactic dehydrogenase concentration and globin concentration; utilizing the blood image set and the blood parameter information set to construct a blood hemolysis composite detection model; based on the blood hemolysis composite detection model, processing the collected blood image and blood parameters to obtain hemolysis detection result information; the hemolysis detection result information is used for representing erythrocyte hemolysis information of the blood corresponding to the collected blood image and blood parameters.

Techniques are disclosed for measuring a concentration of an analyte in a subject based on reflectance spectra obtained from the subject. The spectra are obtained while and / or before and / or after photoreactions are induced in the subject, where the photoreactions change the reflectivity of the subject. The rate of change of the reflectivity is correlated with the concentration of the analyte.

The invention belongs to the technical field of biological medicines, and relates to application of (+)-Sparteine (SPA) or pharmaceutically acceptable salts thereof in preparation of medicines for preventing, relieving or treating hepatic fibrosis. The invention proves that (+)-Sparteine can activate natural killer (NK) cells in a chronic inflammatory fibrosis environment and enhance adhesion and cytotoxic effects of the (+)-Sparteine on activated hepatic stellate cells (HSCs), so that serum biochemical indexes (AST, ALT and total bilirubin) of mice with hepatic fibrosis are remarkably improved, and collagen deposition of hepatic tissues is reduced. The invention provides a new strategy and a molecular target for the treatment of hepatic fibrosis.

The application discloses a kind of polyether sulfone microspheres, preparation method and application, comprising the following steps: step 1: vinyl imidazole bromide salt, acrylic acid and azobisdimethylvaleronitrile are dissolved in solvent, stirring is carried out under nitrogen protection condition, fully reacts, precipitates, and is filtered to obtain polymer;Step 2: the polymer obtained in step 1 is dissolved in solvent to obtain polymer solution;Step 3: the polymer solution obtained in step 2 and polyether sulfone solution are blended, and polyether sulfone microspheres are obtained by electrospinning;The polyether sulfone microspheres obtained by the application have a diameter of 500-800 μm, have a loose porous structure, have a large specific surface area, and have good bilirubin adsorption effect.

The invention relates to the technical field of biology, and particularly discloses a construction method and application of a recombinant Escherichia coli strain with high yield of bilirubin, and the construction method of the strain comprises the following steps: knocking out a heme precursor efflux gene in Escherichia coli, co-expressing the following modules in the Escherichia coli, introducing a gene gdha for enhancing coenzyme factor circulation, and carrying out expression to obtain the recombinant Escherichia coli strain with high yield of bilirubin. According to the method disclosed by the invention, heme precursor exclusion genes are knocked out in escherichia coli, meanwhile, heme oxygenase and biliverdin reductase are modularly assembled by adopting a protein covalent coupling technology, and the yield of bilirubin is increased by increasing synthesis of coenzyme.

This invention discloses a pediatric jaundice treatment device and method for pediatric clinicians, relating to the field of medical device technology. The invention includes a base with an outer shell fixedly connected to its top. An opening and closing plate is connected to the inner wall of the outer shell via hinges. An inner light-transmitting shell is located on the top of the base, slightly smaller than the outer shell, and has a gap in between. This invention achieves dynamic tracking of the infant's torso by setting a U-shaped block and a rotating alignment mechanism. When the infant's sleeping position changes from supine to lateral, the pressure-sensing mattress detects the change in torso position in real time. A second controller transmits this signal to a first controller, driving a micro-motor to rotate a second lead screw, causing the U-shaped block to rotate to the corresponding angle. Simultaneously, the first motor drives the first lead screw to lower the mounting shell and rotating block to a position facing the side of the torso, ensuring that the light group is always aligned with the core area of ​​bilirubin accumulation.

The invention provides a multispectral peritoneal drainage monitor, which comprises an openable host and a disposable drainage sample box, and realizes reagent-free, continuous and quantitative monitoring of hemoglobin, bilirubin and turbidity in drainage liquid through an 8-waveband multispectral light source, a precise capacitance determining electrode and an anti-fouling coating in combination with an equipment specificity algorithm. And four risk indexes of HBI, BBI, TUI and Trend are output, and three-level sound-light alarm is matched, so that the objective and accurate recognition capability of postoperative complications is improved.

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

The application belongs to the technical field of biological medicine, and relates to a hemoperfusion adsorbent, a preparation method and application thereof. The hemoperfusion adsorbent is a microsphere structure, the carrier of the microsphere is a chitosan microsphere, the ligand is type I collagen, and the particle size of the microsphere is 250-1000 mu m. The hemoperfusion adsorbent provided in the application has the characteristics of large adsorption amount of bilirubin, high selective adsorption, small adsorption of albumin and the like based on the synergistic effect of collagen and chitosan, has excellent specific adsorption effect of bilirubin, is low in cost, and has good clinical application prospect.

One aspect relates to: olsalkene; a preparation method therefor; a composition for preventing or treating thrombocytopenia, comprising same; and use thereof. According to one aspect, it has been identified that olsalkene is not cleaved by azoreductase (AzoR) and binds to biliverdin reductase (BLVRB) in the body, thereby inhibiting the reduction of biliverdin (BV) to bilirubin (BR). In addition, it has been identified that platelet production is promoted through the inhibition of biliverdin reductase B activity. Therefore, the olsalkene can be effectively used as a therapeutic agent for thrombocytopenia or as a health functional food through the role of promoting platelet production by inhibiting the activity of biliverdin reductase B.

Provided are: a bilirubin standard solution for a urine qualitative test, the bilirubin standard solution containing at least one substance selected from the group consisting of indirect bilirubin and ditaurobilirubin, a yellow pigment, and a solvent; a kit for a urine qualitative test, the kit containing the standard solution; and a method for a urine qualitative test and a method for controlling the accuracy of urine qualitative test paper, each method comprising using the standard solution.

The invention provides an application of a biliverdin reductase inhibitor in preparation of a medicine for treating hemorrhagic stroke, relates to the technical field of biological medicines, and discloses that biliverdin reductase generates pathological nuclear translocation in the hemorrhagic stroke, and a lipid peroxidation pathway is activated through co-localization of the biliverdin reductase and a lipid metabolism key enzyme ACSL4, so that the biliverdin reductase inhibitor can be used for treating the hemorrhagic stroke. The nerve cell ferroptosis is driven; the biliverdin reductase is used as a novel treatment target, and the inhibitor can effectively relieve iron overload, improve lipid peroxidation, recover GPX4 expression and reduce nerve cell ferroptosis by specifically blocking biliverdin reductase expression or nuclear translocation on the premise of not remarkably interfering the physiological cytoplasm antioxidant function of biliverdin reductase. And finally, the neurological impairment of an animal model is remarkably improved, and the method has the clinical safety advantages of mechanism novelty, curative effect verifiability, targeting accuracy and avoidance of high bilirubin toxicity risk.

The application provides a method for detecting adsorption performance of an adsorbent, comprising: constructing a first adsorption device, wherein the first adsorption device comprises a cation resin adsorber and a neutral macroporous resin adsorber connected in series; performing equal-ratio reduction processing on the first adsorption device according to a preset ratio value to obtain a second adsorption device; obtaining simulated plasma, wherein the simulated plasma contains a preset concentration of a to-be-detected product, and the to-be-detected product comprises bilirubin and / or bile acid; injecting the simulated plasma into the second adsorption device for adsorption processing according to preset circulation parameters to obtain a first concentration of the to-be-detected product in the simulated plasma; determining a first simulated adsorption rate of the to-be-detected product according to the preset concentration of the to-be-detected product and the first concentration of the to-be-detected product; obtaining a calibration factor, and calibrating the first simulated adsorption rate of the to-be-detected product according to the calibration factor to determine an adsorption rate of the to-be-detected product. The application can pre-evaluate the effect of the adsorbent in the DPMAS on removing bilirubin and bile acid.

The invention discloses a nano multi-drug synergistic targeting delivery system based on bilirubin prodrugs and a preparation method of the nano multi-drug synergistic targeting delivery system. The system is formed by self-assembly of an amphiphilic conjugate, the conjugate takes a second-generation lysine dendrimer (G2K) as a hydrophilic skeleton, and the branched end of the conjugate is covalently modified with a hydrophobic antioxidant bilirubin (Br) through a reactive oxygen species (ROS)-sensitive thioketal bond (TK) and is further coupled with a targeting ligand serine (L-serine). The delivery system can specifically recognize damaged kidney tissue, and accurate enrichment of therapeutic drugs in acute kidney injury (AKI) focuses is achieved. After entering a focus, the carrier drives the explosive release of the medicine by utilizing a dual response mechanism of TK bond breakage and bilirubin polarity overturning, and meanwhile, the endogenous anti-oxidation effect of carrier components is exerted. The delivery system provided by the invention has the characteristics of high drug loading capacity, good biocompatibility, strong targeting property and multi-drug synergistic treatment, and has a wide application prospect in the field of kidney disease treatment.

The application provides a plasma adsorber for double adsorption of bilirubin and cytokines and an application thereof. The plasma adsorber comprises a column body and a double-function adsorbent. The column body is provided with an interface for connecting an extracorporeal circulation pipeline at each end. The double-function adsorbent is filled in the column body. A filter screen is arranged at the opening of each end of the column body. The volume of the double-function adsorbent in the column body accounts for 60% to 90% of the volume of the column body. The double-function adsorbent is polystyrene-divinylbenzene macroporous resin with a chlorine content less than 1.5% and capable of adsorbing bilirubin and cytokines simultaneously. The pH value of the double-function adsorbent in an initial state is 5.0 to 6.0. After aging, the pH value of the double-function adsorbent is 4.5 to 6.0. The plasma adsorber provided by the application adopts one adsorption column, can adsorb bilirubin and cytokines simultaneously, reduces the difficulty of medical operation, can reduce the probability of sensitization, and is beneficial to improving the safety of blood purification.

The application discloses a kind of heme oxygenase mutant and its multienzyme coupling preparation of application of bilirubin, belong to biological catalysis engineering field.The application obtains the positive mutant of heme oxygenase by directed evolution technology, can efficiently catalyze heme to synthesize chlorophyllin;Further introduce chlorophyllin reductase, coupling cytochrome P450 reductase, formic acid dehydrogenase, and two kinds of core enzyme are coupled with exogenous auxiliary enzyme, constructs recombinant escherichia coli, catalyzes heme to synthesize bilirubin.In the system, without exogenous addition NADPH, reaction time is about 4h, and bilirubin yield is as high as 2.10g / L, and no intermediate accumulation is observed in catalytic process, reaches the highest yield of the synthesis of bilirubin reported at home and abroad, and the shortest reaction time level.Compared with traditional pig bile extraction, the method of the application breaks through the resource limit, and the operation is simple, the yield is high, realizes the efficient, green synthesis of bilirubin.

The invention discloses an efficient and stable in-vitro cultured calculus bovis preparation process, and belongs to the technical field of biological preparation of traditional Chinese medicines. The process comprises the five steps of genetic engineering compound enzyme liquid preparation, bile pretreatment, bionic enzymatic reaction, crystallization purification and quality regulation and control. The core innovation points are as follows: an engineering strain is constructed through a CRISPR-Cas9 technology to obtain a high-activity compound enzyme solution (the activity is greater than or equal to 80U / mL); an AI intelligent control system is adopted to realize accurate regulation and control, the stability fluctuation of the system is less than or equal to + / -0.5%, and the contamination rate is less than or equal to 0.03%; a composite anti-oxidation system and a supercritical COrefining process are matched, so that the oxidation loss of effective components is reduced. The production period is shortened to 3 days, the finished product bilirubin is larger than or equal to 38.2%, the cholic acid is larger than or equal to 6.6%, the product conforms to the 2025 edition pharmacopoeia standard, acute toxicity is extremely low, skin irritation and sensitization are avoided, the industrialization prospect is good, the product quality is high, safety is high, and natural calculus bovis can be effectively replaced to meet clinical requirements.

A standardized phototherapy system for delivering a controlled dose of therapeutic light within a therapeutic optical bandwidth to a patient. The phototherapy system includes a therapeutic light source configured to generate spatially uniform irradiance over is a treatment region. The irradiance generated over the treatment region is controlled by controller via a driver signal and is calibrated using a photonic dosimeter matched to the therapeutic light source. The photonic dosimeter is a photonic dosimeter configured to establish a reference relationship between the driver signal provided to the therapeutic light source and the irradiance generated over the treatment region. The controller can adjust the irradiance of the therapeutic light over the therapy region based on patient data comprising measured concentration of a biological analyte in patient's blood.

The invention discloses a preparation method of a hyper-crosslinked macroporous adsorption resin capable of simultaneously adsorbing bilirubin, bile acid and cytokines in blood purification. The preparation method comprises the following steps: preparing macroporous styrene-divinylbenzene resin with low crosslinking degree from a styrene monomer and a polyethylene phenyl crosslinking agent; then carrying out secondary crosslinking on macroporous styrene-divinylbenzene resin with low crosslinking degree by utilizing a Friedel-Grafts method to prepare hypercrosslinked adsorption resin, and further reacting residual chloromethyl with an amination reagent to improve the adsorption performance of bilirubin and bile acid. The prepared adsorbent can adsorb bilirubin, bile acid and cell factors at the same time, the adsorption rate of the adsorbent to bilirubin is superior to that of an anion resin bilirubin perfusion device used clinically, in combined artificial liver treatment, one perfusion device can replace two perfusion devices, the treatment cost and the operation risk are greatly reduced, and the treatment effect is good. Meanwhile, the biocompatibility is superior to that of anion resin, and the good market application value is achieved.

The invention discloses an anti-Xa factor detection kit, and relates to the technical field of in vitro diagnosis. The anti-Xa factor detection kit comprises a reagent R1 and a reagent R2, the reagent R1 mainly comprises a first buffer solution, inorganic salt, a stabilizer, FXa, a first preservative, vanadate, an inhibitor and alkoxy polyethylene hydroxyl ethanol; the inhibitor is used for inhibiting the blood coagulation effect of the platelet factor 4; the reagent R2 comprises a second buffer solution, an FXa chromophoric substrate, a sugar alcohol substance and a second preservative. The anti-Xa factor detection kit provided by the invention is strong in anti-interference capability and accurate in detection, can realize pretreatment-free direct detection on chyle samples, can resist interference of interferents such as bilirubin and hemoglobin, and can meet the requirements of clinical complex sample detection.